Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewBAM 7 is a Bax activator (EC50 = 3.3 μM); binds at the BH3-binding site. Selective for Bax over other antiapoptotic and proapoptotic proteins. Triggers Bax oligomerization in vitro; induces Bax-mediated apoptosis in mouse embryonic fibroblasts.
M. Wt | 405.47 |
Formula | C21H19N5O2S |
Storage | Store at +4°C |
Purity | ≥99% (HPLC) |
CAS Number | 331244-89-4 |
PubChem ID | 5754137 |
InChI Key | KOCVKGYKBLJEPK-LYBHJNIJSA-N |
Smiles | CC(/C1=N\NC2=C(OCC)C=CC=C2)=NN(C3=NC(C4=CC=CC=C4)=CS3)C1=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Gavathiotis et al (2012) Direct and selective small-molecule activation of proapoptotic BAX. Nat.Chem.Biol. 8 639 PMID: 22634637
Keywords: BAM 7, BAM 7 supplier, BAM7, bax, proapoptotic, apoptosis, activators, BH3, binding, site, inducers, oligomerization, selective, Bcl-2, Family, Apoptosis, Inducers, 4810, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for BAM 7.
There are currently no reviews for this product. Be the first to review BAM 7 and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.